Wegovy is administered as a once-weekly subcutaneous injection, typically starting at a low dose of 0.25 mg and gradually increasing over a standard 16-week period to the maintenance dose of 2.4 mg (though this escalation can be delayed if not tolerated)
Semaglutide can cause nausea, diarrhea, vomiting, stomachache and constipation, among other ailments

Indications and Usage Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg and Ozempic (semaglutide) tablets 4 mg or 9 mg are indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes Ozempic injection is indicated: to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established CV disease to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Ozempic tablets are indicated: to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes who are at high risk for these events Important Safety Information for Ozempic WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration- dependent thyroid C-cell tumors at clinically relevant exposures

The bad thing about arthritis is there arent great treatments
As you navigate the complexities of chronic illness, remember that healing is rarely a linear path